Abstract
In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Current Vascular Pharmacology
Title: Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Volume: 6 Issue: 3
Author(s): Jean-Frederic Boyer, Alain Cantagrel and Arnaud Constantin
Affiliation:
Keywords: Rheumatoid arthritis, cardiovascular diseases, disease-modifying anti-rheumatic drugs, glucocorticoids, nonsteroidal anti-inflammatory drugs, biologics
Abstract: In chronic inflammatory diseases such as rheumatoid arthritis (RA), systemic inflammation appears as an independent risk factor, contributing to increased cardiovascular mortality. This high cardiovascular mortality reveals the existence of accelerated atherosclerosis, the pathogenesis of which may be associated with traditional risk factors such as smoking, hypertension, dyslipidemia, deterioration of insulin sensitivity, and less traditional risk factors such as hyperhomocysteinemia, inflammatory conditions and endothelial dysfunction. Control of systemic inflammation theoretically provides a means of preventing this higher cardiovascular mortality among RA patients. In this review we address the question of the impact of anti-rheumatic drugs currently used in RA, such as non-steroidal anti-inflammatory drugs (e.g. non-selective or cyclooxygenase-2 selective inhibitors), steroidal anti-inflammatory drugs (glucocorticoids), traditional disease-modifying anti-rheumatic drugs (e.g. methotrexate) or biologics (e.g. anti-tumour necrosis factor alpha anti-tumour necrosis factor alpha) on cardiovascular diseases in RA patients. We also discuss the specific mechanisms involved in the differential cardiovascular effects of these therapeutic agents.
Export Options
About this article
Cite this article as:
Boyer Jean-Frederic, Cantagrel Alain and Constantin Arnaud, Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis, Current Vascular Pharmacology 2008; 6 (3) . https://dx.doi.org/10.2174/157016108784911975
DOI https://dx.doi.org/10.2174/157016108784911975 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Iodine in Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Gastric Carcinoma at the Era of Targeted Therapies
Current Drug Targets Therapeutic Targeting of the Soluble Guanylate Cyclase
Current Medicinal Chemistry Henoch-Schönlein Purpura in Children: An Updated Review
Current Pediatric Reviews Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews How Do HIV-Infected Smokers React to Cigarette Price Increases? Evidence from the Aproco-Copilote-ANRS CO8 Cohort
Current HIV Research Study on the Effect of HPMC on Compression Coated Floating Pulsatile Delivery of Bisoprolol
Current Drug Therapy Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine Phentermine and Topiramate Extended-Release for the Obesity: New Kids on the Block
Recent Patents on Cardiovascular Drug Discovery Preeclampsia - Current Management and Future Approach
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Clinical Presentation, Quality of Care, Risk Factors and Outcomes in Women with Acute ST-Elevation Myocardial Infarction (STEMI): An Observational Report from Six Middle Eastern Countries
Current Vascular Pharmacology